← Back to Search

AI-A group for Artificial Intelligence (CADx-RCT Trial)

N/A
Waitlist Available
Led By Daniel von Renteln, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Indication for full colonoscopy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 100 weeks
Awards & highlights

Summary

Computer-aided image-enhanced endoscopy can predict the nature of colorectal polyps with over 90% accuracy. This technology uses artificial intelligence (AI) to analyze video recordings of polyps, learning to make diagnoses in real-time. This means that doctors can get immediate predictions about small polyps during the procedure, reducing the need for separate pathology exams and saving costs, ultimately improving patient care. Traditionally, non-computer-aided diagnosis of polyps varies greatly between doctors. AI can help reduce this variability by providing consistent and accurate computer-aided diagnoses (CADx). In the past, CADx systems could only tell if polyps were cancerous or not. However, recent advancements show that current CADx systems are as accurate as doctors. For widespread use, these systems need to recognize different types of polyps, including serrated ones, which are more challenging to identify. Newer CADx systems are being developed to recognize these serrated polyps, but they still need further validation for autonomous use.

Eligible Conditions
  • Artificial Intelligence
  • Colorectal Adenomas

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 100 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 100 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Accuracy of autonomous CADx system (AI-A) optical diagnosis compared with the real-time CADx diagnosis (AI-H)
Secondary study objectives
Agreement of surveillance interval recommendations of AI-A and AI-H compared with the pathology-based recommendations
Cost-effectiveness of OD ((AI-A and AI-H)
Proportion of patients for whom an immediate surveillance recommendation can be directly provided for each approach, and how often histopathology-based polyp examination would have been avoided.
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: AI-H groupExperimental Treatment1 Intervention
Very small polyp will be evaluated by the CADx (AI) system, and its diagnosis will be shown to the doctor. The doctor can agree or disagree with the CADx diagnosis and will make the final decision.
Group II: AI-A groupExperimental Treatment1 Intervention
The doctor will show the polyp to the CADx (AI) system, which will make the diagnosis without any changes from the doctor. The actual tissue samples will then be analyzed in the lab to confirm the diagnosis, and the results will be compared to the CADx system's predictions

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
372 Previous Clinical Trials
130,631 Total Patients Enrolled
2 Trials studying Artificial Intelligence
900 Patients Enrolled for Artificial Intelligence
Roupen Djinbachian, MDUNKNOWN
Mahsa Taghiakbari, MD PHDUNKNOWN
~267 spots leftby Sep 2025